Summary of Product Characteristics (SmPC) - Dalivit drops
1 NAME OF THE MEDICINAL PRODUCT
Dalivit Drops
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 0.6 ml contains:
Vitamin A Palmitate BP 5,000 units Ergocalciferol (Vitamin D2) Ph Eur 400 units Thiamine hydrochloride BP 1 mg (Vitamin B1)
Riboflavin (Vitamin B2) BP 400 micrograms Pyridoxine hydrochloride BP 500 micrograms (Vitamin B6)
Ascorbic acid (Vitamin C) BP 50 mg Nicotinamide BP 5 mg
Excipient(s):
This product contains Sucrose.
This product also contains E219 Sodium Methylhydroxybenzoate. For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral Drops, Emulsion (Oral Drops)
Yellowish orange coloured liquid, slightly viscous.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
As a supplement for the prevention of vitamin deficiency states. As an aid to the maintenance of normal health and growth in infants and young children.
4.2 Posology and method of administration
Method of administration
To be administered by oral route.
Dose:
Infants from 6 weeks to one year : 0.3 ml daily (7 drops).
Older children, adults and elderly: 0.6 ml daily (14 drops) or as directed by the physician.
4.3 Contraindications
Hypersensitivity to any of the active substances or any of the excipients.
Contra-indicated in hypercalcaemia.
Contra-indicated in women who are (or may become) pregnant (see 4.6).
4.4 Special warnings and precautions for use
When multivitamin preparations are prescribed allowance must be made for vitamins from other sources. No other preparations contain vitamin A should be taken with this preparation except under medical supervision.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Label will state:
- Do not exceed the stated dose.
- Keep out of the Reach and Sight of children.
- Contains Sodium methylhydroxybenzoate (E219). May cause allergic reactions (possibly delayed).
- Contains Sucrose: If you have been told by doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
4.5 Interaction with other medicinal products and other forms of interaction
Vitamin A
Neomycin: Absorption of Vitamin a possibly reduced by neomycin
Retinoids: Risk of hypervitaminosis A when vitamin A given with retinoids
Vitamin D:
Barbiturates, carbamazepine, phenytoin, primidone: Vitamin D requirements possibly increased when given with either of the listed medications.
Diuretics thiazide: Increased risk of hypercalacaemia when vitamin D given with thiazide and related diuretics.
4.6 Fertility, Pregnancy and lactation
In view of evidence suggesting that high levels of Vitamin A may cause birth defects, women who are (or may become) pregnant are advised not to take Vitamin A supplements (including tablets and fish-liver oil drops), except on the advice of a doctor or an antenatal clinic ( see section 4.3).
Vitamin D is secreted in breast milk and may cause hypercalcaemia in infants.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
No undesirable effects due to the administration of Dalivit Drops have been reported, and none can be expected if the dosage schedule is adhered to.
Excessive dose of Vitamins A and D can lead to hypervitaminosis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Symptoms of Vitamin overdosage may include anorexia, nausea, vomiting, rough dry skin, polyuria, thirst, loss of hair, painful bones and joints, as well as raised plasma and urine calcium and phosphate concentration.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Multivitamins
ATC Code: A11A multivitamins combinations
5.2 Pharmacokinetic properties
None stated.
5.3 Preclinical safety data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sucrose
Polysorbate 80
Sodium hydroxide
Sodium methyl hydroxybenzoate (E219)
Deionized water
6.2 Incompatibilities
None known.
6.3 Shelf life
2 years.
6.4 Special precautions for storage
Store in dry place below 25°C. Protect from light.
6.5 Nature and contents of container
Pack size 25ml 2 bottles per carton
Pack size 25ml 1 bottle per carton
Pack size l0ml 1 bottle per carton
Pack size 50ml 1 bottle per carton
6.6 Special precautions for disposal
This medicine must not be used after the date (Exp) printed on the back. Any unused product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Biobos Limited
94 Rickmansworth Road,
Watford,
Hertfordshire, WD18 7JJ,
United Kingdom.
8 MARKETING AUTHORISATION NUMBER(S)
PL 43217/0007
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
13/03/2007
10 DATE OF REVISION OF THE TEXT
18/11/2021